and provide palliative care to pediatric populations. NINR is launching this effort to increase the use of palliative care for children living with serious illness or life-limiting conditions. The *Palliative Care: Conversations Matter* evaluation will assess the information and materials being disseminated as part of the official campaign. Survey findings will help (1) Determine if the campaign is effective, relevant, and useful to health care providers who recommend and provide palliative care to pediatric populations; (2) to better understand the information needs of health care providers to inform future campaign efforts; and (3) examine how effective the campaign materials are in starting and continuing a pediatric palliative care conversation and addressing the communications needs of health care providers around this topic.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 200.

Estimated Annualized Burden Hours

TABLE A–12–1—ESTIMATES OF ANNUAL BURDEN HOURS

Type of respondents	Number of respondents	Frequency of response	Average time per response (in hours)	Total burden hours
Physicians	150	2	20/60	100
Nurses	150	2	20/60	100
Total	300			200

* The average time for completing one of the surveys is 20 minutes; this includes reading the consent form on page 1 of the survey.

Dated: August 19, 2013.

Amanda Greene,

NINR PRA Liaison, Science Evaluation Officer, NINR, NIH.

[FR Doc. 2013–21005 Filed 8–27–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive Patent License: Use of Exenatide for the Treatment of Neurodegenerative Diseases

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR Part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Peptron, Inc., a company having a place of business in Daejeon, South Korea, to practice the inventions embodied in U.S. Provisional Patent Application No. 60/309,076, filed July 31, 2001, entitled ''Long-Acting Insulinotropic Peptides and Uses Thereof'' (HHS Ref. No. E–049–2001/0–US–01); U.S. Patent No. 7,576,050, issued August 18, 2009, entitled ''GLP–1 Exendin–4 Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–US–03); U.S. Patent No. 8,278,272, issued October 2, 2012, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–US–14); U.S. Patent Application No. 13/594,313, filed August 24, 2012, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–US–21); PCT Patent Application No. PCT/US2002/024141, filed July 30, 2002, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–PCT–02); Australian Patent No. 2002317599, issued July 17, 2008, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–AU–04); Australian Patent No. 2008202893, issued April 26, 2012, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–AU–10); Australian Patent Application No. 2012202081, filed April 11, 2012, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–AU–20); Canadian Patent Application No. 2455963, filed January 29, 2004, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–CA–05); European Patent No. 1411968, issued September 17, 2008, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–EP–06) and validated in Germany (HHS Ref. No. E–049–2001/0–DE–11), France (HHS Ref. No. E–049–2001/0–FR–12), and Great Britain (HHS Ref. No. E–049–2001/0–GB–13); European Patent No. 2022505, issued December 14, 2011, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–EP–09) and validated in Germany (HHS Ref. No. E–049–2001/0–DE–17), France (HHS Ref. No. E–049–2001/0–FR–18), and Great Britain (HHS Ref. No. E–049–2001/0–GB–19); European Patent Application No. 10177860.3, filed September 21, 2010, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–EP–16); Indian Patent Application No. 0488/DELNP/2004, filed February 27, 2004, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–IN–07); Japanese Patent Application No. 2003–517083, filed February 2, 2004, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–JP–08); Japanese Patent Application No. 2009–262568, filed November 18, 2009, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–JP–15; and Japanese Patent Application No. 2013–007743, filed January 18, 2013, entitled ''GLP–1, Exendin–4, Peptide Analogs and Uses Thereof'' (HHS Ref. No. E–049–2001/0–JP–22). The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Exclusive Patent License may be worldwide, and the field of use may be limited to ''Methods of using exenatide for the treatment of neurodegenerative disease in humans.''

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 27, 2013 will be considered.

ADDRESSES: Requests for copies of the patent application(s), inquiries, comments, and other materials relating to the contemplated Exclusive Patent License should be directed to: Tara L. Kirby, Ph.D., Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–4426; Facsimile:

(301) 402–0220; Email: *tarak@mail.nih.gov.* A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the World Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: This technology relates to the use of glucagon-like peptide–1 (GLP–1), exendin–4, and analogs for the treatment of neurodegenerative diseases. These peptides are GLP–1 receptor agonists and incretin mimetics, and enhance glucose-dependent insulin secretion and regulate glucagon secretion. As such, they have been used in the treatment of type 2 diabetes. The inventors have shown that these peptides also exert neurotrophic and neuroprotective effects in a variety of predictive models of neurodegeneration, and thus may represent potential therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), peripheral neuropathy (associated or unassociated with diabetes) and stroke.

The prospective Exclusive Patent License may be granted unless the NIH receives written evidence and argument, within thirty (30) days from the date of this published notice, that establishes that the grant of the contemplated license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404.

Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the Exclusive Patent License. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 22, 2013.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013–20945 Filed 8–27–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel Detection of Pathogen Induced Cancer.

Date: October 1, 2013.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W034, Rockville, MD 20850, (Telephone Conference Call).

Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Rockville, MD 20850, 240–276–6368, *Stoicaa2@mail.nih.gov.*

Name of Committee: National Cancer Institute Special Emphasis Panel Planning for a National Center for Particle Beam Radiation Therapy Research.

Date: October 3, 2013.

Time: 9:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 6W032, Rockville, MD 20850, (Telephone Conference Call).

Contact Person: Thomas A. Winters, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W412, Bethesda, MD 20892–9750, 240–276–6386, *twinters@mail.nih.gov.*

Name of Committee: National Cancer Institute Special Emphasis Panel Informatics Technology for Cancer Research.

Date: October 22, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda Marriott Suites-Hotel, 6711 Democracy Blvd., Bethesda, MD 20817.

Contact Person: Viatcheslav A Soldatenkov, MD, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W254, Bethesda, MD 20892–8329, 240–276–6378, *soldatenkovv@mail.nih.gov.*

Name of Committee: National Cancer Institute Special Emphasis Panel NCI Omnibus Grants on Cancer Genetics and Etiology.

Date: October 22–23, 2013.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites Alexandria—Old Town, 1900 Diagonal Road, Alexandria, VA 22314.

Contact Person: Marvin L. Salin, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W236, Bethesda, MD 20892–8329, 240–276–6369, *msalin@mail.nih.gov.*

Name of Committee: National Cancer Institute Initial Review Group Subcommittee F–Institutional Training and Education.

Date: October 28–29, 2013.

Time: 7:30 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Arlington Capital View, 2850 South Potomac Avenue, Arlington, VA 22202.

Contact Person: Timothy C. Meeker, Ph.D., MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Bethesda, MD 20850, 240–276–6464, *meekert@mail.nih.gov.*

Name of Committee: National Cancer Institute Special Emphasis Panel Research Answers to NCI's Provocative Questions-Group A (R01).

Date: October 31–November 1, 2013.

Time: 7:30 a.m. to 5:30 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Clifford W Schweinfest, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W108, Bethesda, MD 20892–9750, 240–276–6378, *schweinfestcw@mail.nih.gov.*

Name of Committee: National Cancer Institute Special Emphasis Panel Collaborative Human Tissue Network (CHTN) (UM1).

Date: November 4–5, 2013.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room: Nov 4–6W030 & Nov 5–7W030, Rockville, MD 20850, (Telephone Conference Call).

Contact Person: Donald L Coppock, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH,